Research & Development
-
Stock via Getty Images
A recent gene therapy death shines a light on AAV safety
This technology brings both benefits and drawbacks for the field, which is also testing alternatives.
By Kelly Bilodeau • March 31, 2025 -
Victor Golmer via Getty Images
In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
By Amy Baxter • March 31, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Ignatiev via Getty Images
Sponsored by PfizerHarnessing the power of AI to detect ATTR-CM
From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.
March 31, 2025 -
Stock via Getty Images
FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.
The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.
By Meagan Parrish • March 28, 2025 -
Alex Wong / Staff via Getty Images
HHS announces sweeping reorganization, including cuts of 10K workers
Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.
By Rebecca Pifer • March 27, 2025 -
magicmine, iStock / Getty Images Plus via Getty Images
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.
By Michael Gibney • March 27, 2025 -
Jacob Bell/PharmaVoice
Biogen plots new global headquarters in Kendall Square
The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.
By Jacob Bell • March 25, 2025 -
Permission granted by Novavax
ProfileThe industry heavyweight behind Novavax’s push to bounce back
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
By Alexandra Pecci • March 25, 2025 -
Stock via Getty Images
Biotechs emerging from stealth take aim at pharma’s prime targets
The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.
By Kelly Bilodeau • March 24, 2025 -
Stock via Getty Images
How pharma could feel the pain of a recession
Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.
By Meagan Parrish • March 21, 2025 -
Courtesy of Sarepta
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.
By Michael Gibney • March 20, 2025 -
Stock via Getty Images
The key factors shaping China’s biopharma boom
Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.
By Alexandra Pecci • March 19, 2025 -
Permission granted by Diakanos
Q&AHow non-traditional investors fuel up-and-coming biotechs when VC funding dries up
Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.
By Michael Gibney • March 18, 2025 -
Stock via Getty Images
Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do
Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.
By Kelly Bilodeau • March 17, 2025 -
Permission granted by Roche
Q&ARoche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
By Amy Baxter • March 17, 2025 -
Stock via Getty Images
Takeda’s $770M deal deepens Big Pharma’s omics push
The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.
By Alexandra Pecci • March 13, 2025 -
Stock via Getty Images
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
By Amy Baxter • March 11, 2025 -
Permission granted by Biogen
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
By Meagan Parrish • March 10, 2025 -
Kevin C. Cox via Getty Images
The top 3 impacts of Trump’s health data purge
Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.
By Michael Brady • March 6, 2025 -
Mario Tama via Getty Images
With patent losses on the horizon, Amgen refocuses its business strategy
The company’s vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
By Alexandra Pecci • March 5, 2025 -
Courtesy of AbbVie
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
By Jonathan Gardner • March 5, 2025 -
Stock via Getty Images
Americans want to participate in clinical trials — so why don’t they?
A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.
By Kelly Bilodeau • March 4, 2025 -
Permission granted by Voyager Therapeutics
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.
By Michael Gibney • March 4, 2025 -
Permission granted by Teva
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
By Meagan Parrish • Feb. 28, 2025 -
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
By Michael Gibney • Feb. 27, 2025
